BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 22150126)

  • 1. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile.
    Calderón MA; Simons FE; Malling HJ; Lockey RF; Moingeon P; Demoly P
    Allergy; 2012 Mar; 67(3):302-11. PubMed ID: 22150126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
    Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
    J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy.
    Pokladnikova J; Krcmova I; Vlcek J
    Ann Allergy Asthma Immunol; 2008 May; 100(5):482-9. PubMed ID: 18517082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New administration routes for immunotherapy].
    Martorell Aragonés A
    Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
    Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune mechanisms of allergen-specific sublingual immunotherapy.
    Moingeon P; Batard T; Fadel R; Frati F; Sieber J; Van Overtvelt L
    Allergy; 2006 Feb; 61(2):151-65. PubMed ID: 16409190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician.
    Moingeon P
    J Allergy Clin Immunol Pract; 2013; 1(3):228-41. PubMed ID: 24565479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
    Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
    J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma.
    Bahceciler NN; Cobanoglu N
    Immunotherapy; 2011 Jun; 3(6):747-56. PubMed ID: 21668312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose dependence of efficacy but not of safety in sublingual immunotherapy.
    Frati F; Incorvaia C; Marcucci F; Sensi L; Di Cara G; Puccinelli P; Dal Bo S
    Monaldi Arch Chest Dis; 2006 Mar; 65(1):38-40. PubMed ID: 16700192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One century of allergen-specific immunotherapy for respiratory allergy.
    Incorvaia C; Frati F
    Immunotherapy; 2011 May; 3(5):629-35. PubMed ID: 21554092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC.
    Savolainen J; Jacobsen L; Valovirta E
    Allergy; 2006 Oct; 61(10):1184-90. PubMed ID: 16942566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sublingual immunotherapy for Japanese cedar pollinosis.
    Okubo K; Gotoh M
    Allergol Int; 2009 Jun; 58(2):149-54. PubMed ID: 19390236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production.
    Burastero SE; Mistrello G; Falagiani P; Paolucci C; Breda D; Roncarolo D; Zanotta S; Monasterolo G; Rossi RE
    Ann Allergy Asthma Immunol; 2008 Apr; 100(4):343-50. PubMed ID: 18450120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing and efficacy in specific immunotherapy.
    Demoly P; Calderon MA
    Allergy; 2011 Jul; 66 Suppl 95():38-40. PubMed ID: 21668851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological mechanisms of sublingual allergen-specific immunotherapy.
    Novak N; Bieber T; Allam JP
    Allergy; 2011 Jun; 66(6):733-9. PubMed ID: 21251016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
    Esch RE; Bush RK; Peden D; Lockey RF
    Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of sublingual grass pollen immunotherapy after anaphylaxis.
    Nichani JR; de Carpentier J
    J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
    Asero R
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.